Sandoz Ag

Generics (UK) Limited

Generics Limited

Abhinay C Pise

Sachin Bhuta

Dominic De Souza

Shreerang V Joshi

Dattatraya N Chavan

Shashikant D Metkar

Martin Langner

Rajesh Rao

Maheshkumar Gadakar

Parven Kumar Luthra

Jason Gray

Sudhir Nambiar

Sanjay Talukdar

Sudhir Sawant

Deepak Venkataraman

Ramakrishnan Arul

Ajay Singh Rawat

Dattatraya Chavan

Shashikant Metkar

The present invention relates to a process for the preparation of a hydrogen chloride (HCl) salt of a compound of formula (I) wherein Yand Yare independently F or Cl, preferably F, said compound of formula (I) containing the cis-isomer and the trans-isomer, wherein the process comprises (1) providing the compound of formula (I) comprised in a first suitable solvent; and (2) treating the compound of formula (I) comprised in the first suitable solvent with HCl comprised in a second suitable solvent to obtain the HCl salt of the compound of formula (I). 

Purification of posaconazole and of posaconazole intermediates

The present invention relates to process for the preparation of a chiral compound of formula (IX) or a salt thereof, wherein Yand Yare independently F or Cl, preferably F, the crystalline compound of formula (IX) as such, and its use for the preparation of an antifungal agent. 

Preparation of posaconazole intermediates

Processes for the preparation of Silodosin and its intermediates comprising reductive amination of compound of Formula (VIII) with a compound of Formula (VII) or a compound of Formula (XV) in a suitable solvent using a reducing agent.

Process for the preparation of indoline derivatives and their intermediates thereof

The present invention relates to novel crystalline forms of the platelet aggregation inhibitor (+)-(S)-methyl-2-(2-chlorophenyl)-(6,7-dihydro-4H-thieno[3,2-c]pyrid-5-yl)acetate, clopidogrel (1), in the form of hydrogen bromide salts, identified as polymorph forms 1, 2 and 3. The present invention further relates to processes for preparing such forms, pharmaceutical compositions comprising such forms, and uses for such forms and compositions. The pharmaceutical compositions may be used, in particular, for inhibiting platelet aggregation or for treating, preventing or managing thrombosis, atherothrombosis, an atherothrombotic event, ischaemic stroke, myocardial infarction, non-Q-wave myocardial infarction, atherosclerosis, peripheral arterial disease, or unstable angina. The present invention also relates to methods of treating said disorders. Formula (1). 

Crystalline polymorphs of clopidogrel

This invention provides a process for reducing an exocyclic double bond at the 5-position of a thiazolidinedione moiety of a thiazolidinedione precursor comprising the steps of: Preferred solvent media include aqueous N,N-dimethylformamide. Sodium dithionite is a preferred dithionite source.

Process for preparing thiazolidinediones

Growing community of inventors

Navi Mumbai, India

Abhinay C Pise